Transaction #20594 · Form 4 · 0001213900-25-121974
RELMADA THERAPEUTICS, INC. · Purchase · Common Stock
RELMADA THERAPEUTICS, INC. · Transacted December 15, 2025 · Filed December 16, 2025
What does this filing report?
An SEC Form 4 filing for RELMADA THERAPEUTICS, INC. records a purchase involving Common Stock on December 15, 2025. The reported quantity was 27,500. The filing date is December 16, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- RELMADA THERAPEUTICS, INC.
- Company CIK
- 0001553643
- Security type
- Non-derivative
- Acquisition type
- Purchase · Code P
- Quantity acquired
- 27,500
- Reported price
- 4.12 · See footnotes
- Reference value
- 113,300
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 1,300,000
- Ownership description
- Not reported
- SEC acceptance time
- Dec 16, 2025, 9:30 AM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- TRAVERSA SERGIO ↗
Chief Executive Officer · Director
CIK 0001565832
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.
- F2
- Purchase prices range from $4.10 to $4.12 per share, inclusive.
- F3
- The stock appreciation rights vest in 16 equal quarterly installments commencing on March 12, 2026.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.